PE20120171A1 - Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh - Google Patents

Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh

Info

Publication number
PE20120171A1
PE20120171A1 PE2011001599A PE2011001599A PE20120171A1 PE 20120171 A1 PE20120171 A1 PE 20120171A1 PE 2011001599 A PE2011001599 A PE 2011001599A PE 2011001599 A PE2011001599 A PE 2011001599A PE 20120171 A1 PE20120171 A1 PE 20120171A1
Authority
PE
Peru
Prior art keywords
salt
carboxyl groups
acid
derivatives
addition salts
Prior art date
Application number
PE2011001599A
Other languages
English (en)
Inventor
Garcia Juan Bautista Perez
Carrera Francesc Carrera
Martin Digna Jose Garcia
Bernardini Maria Carmen Boix
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of PE20120171A1 publication Critical patent/PE20120171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA SAL DE ADICION CRISTALINA DE FORMULA (I) DE UNA AMINA QUE TIENE UNO O MAS GRUPOS HIDROXILO Y/O CARBOXILICOS CON UN DERIVADO DE ACIDO AMINONICOTINICO, DONDE Ra, Rb, Rc Y Rd SON H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: SAL DE MEGLUMINA DE ACIDO 2-{[3'-ETOXI-3-(TRIFLUOROMETOXI)-1,1'-BIFENIL-4-IL]AMINO}NICOTINICO, SAL DE TROMETAMINA DE ACIDO 2-{[(3,5-DIFLUORO-2-METIL-1,1'-BIFENIL-4-IL]AMINO}NICOTINICO, SAL DE L-ARGININA DE ACIDO 2-[(3,5-DIFLUORO-3'-METOXI-1,1'-BIFENIL-4-IL)AMINO]NICOTINICO, ENTRE OTRAS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHA SAL TIENE ACTIVIDAD INHIBIDORA DE DIHIDROORATO DE DESHIDROGENASA (DHODH) Y ES UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ARTRITIS PSORIASICA, ESCLEROSIS MULTIPLE, ENTRE OTRAS
PE2011001599A 2009-03-13 2010-03-11 Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh PE20120171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382031A EP2228367A1 (en) 2009-03-13 2009-03-13 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors

Publications (1)

Publication Number Publication Date
PE20120171A1 true PE20120171A1 (es) 2012-03-01

Family

ID=40677683

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001599A PE20120171A1 (es) 2009-03-13 2010-03-11 Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh

Country Status (35)

Country Link
US (1) US20120014918A1 (es)
EP (2) EP2228367A1 (es)
JP (1) JP5674685B2 (es)
KR (1) KR101674699B1 (es)
CN (1) CN102348689B (es)
AR (1) AR075738A1 (es)
AU (1) AU2010223528B2 (es)
BR (1) BRPI1006766B8 (es)
CA (1) CA2754804C (es)
CL (1) CL2011002216A1 (es)
CO (1) CO6420337A2 (es)
CY (1) CY1114418T1 (es)
DK (1) DK2406225T3 (es)
EA (1) EA022350B1 (es)
EC (1) ECSP11011365A (es)
ES (1) ES2428746T3 (es)
HK (1) HK1162487A1 (es)
HR (1) HRP20130851T1 (es)
IL (1) IL214519A (es)
ME (1) ME01564B (es)
MX (1) MX2011009146A (es)
MY (1) MY155140A (es)
NZ (1) NZ594493A (es)
PE (1) PE20120171A1 (es)
PL (1) PL2406225T3 (es)
PT (1) PT2406225E (es)
RS (1) RS52949B (es)
SG (1) SG173823A1 (es)
SI (1) SI2406225T1 (es)
SM (1) SMT201300104B (es)
TW (1) TWI428127B (es)
UA (1) UA105786C2 (es)
UY (1) UY32467A (es)
WO (1) WO2010102826A1 (es)
ZA (1) ZA201105744B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
EP2594271A1 (en) * 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
KR101251851B1 (ko) 2011-11-30 2013-04-10 현대자동차주식회사 Ｉｓｇ 시스템 및 이의 제어방법
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2983649A1 (en) * 2013-04-12 2016-02-17 Actavis Group PCT ehf Pemetrexed formulation
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
CN112969699A (zh) 2018-10-09 2021-06-15 亚狮康私人有限公司 瓦利替尼的丙二酸盐
MX2021007536A (es) * 2018-12-21 2021-09-23 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.
US20230390276A1 (en) * 2020-10-15 2023-12-07 Aslan Pharmaceuticals Pte. Ltd. Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
PL352430A1 (en) * 1999-06-10 2003-08-25 Warner Lambert Co Method of inhibiting agreggation of amyloid proteins and visualising amyloid deposits
EP1381356B1 (en) 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP2004099586A (ja) * 2002-05-21 2004-04-02 Sumitomo Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害剤
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
US20070219224A1 (en) 2004-05-21 2007-09-20 Uab Research Foundation, The Compositions and Methods Relating to Pyrimidine Synthesis Inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
KR20070065888A (ko) 2004-10-19 2007-06-25 아벤티스 파마슈티칼스 인크. 염증성 장질환을 치료하기 위한(ｚ)-2-시아노-3-하이드록시-부트-2-엔산-(4'-트리플루오로메틸페닐)-아미드의 용도
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
ZA201105744B (en) 2012-04-25
CY1114418T1 (el) 2016-08-31
JP5674685B2 (ja) 2015-02-25
WO2010102826A1 (en) 2010-09-16
UY32467A (es) 2010-05-31
MX2011009146A (es) 2011-09-15
IL214519A0 (en) 2011-09-27
EP2406225B1 (en) 2013-06-26
CO6420337A2 (es) 2012-04-16
US20120014918A1 (en) 2012-01-19
ME01564B (me) 2014-09-20
AU2010223528A1 (en) 2011-08-25
AU2010223528B2 (en) 2017-02-16
RS52949B (en) 2014-02-28
HRP20130851T1 (hr) 2013-10-25
JP2012520252A (ja) 2012-09-06
TW201034669A (en) 2010-10-01
KR101674699B1 (ko) 2016-11-09
KR20110126694A (ko) 2011-11-23
CL2011002216A1 (es) 2012-03-09
AR075738A1 (es) 2011-04-20
EP2406225A1 (en) 2012-01-18
EP2228367A1 (en) 2010-09-15
EA201101297A1 (ru) 2012-04-30
ES2428746T3 (es) 2013-11-11
CA2754804A1 (en) 2010-09-16
EA022350B1 (ru) 2015-12-30
PL2406225T3 (pl) 2013-12-31
SI2406225T1 (sl) 2013-10-30
CN102348689A (zh) 2012-02-08
NZ594493A (en) 2013-11-29
CA2754804C (en) 2018-07-24
IL214519A (en) 2015-03-31
BRPI1006766B1 (pt) 2021-03-23
SMT201300104B (it) 2013-11-08
DK2406225T3 (da) 2013-09-30
MY155140A (en) 2015-09-15
UA105786C2 (uk) 2014-06-25
TWI428127B (zh) 2014-03-01
HK1162487A1 (en) 2012-08-31
CN102348689B (zh) 2014-05-14
ECSP11011365A (es) 2011-10-31
SG173823A1 (en) 2011-09-29
BRPI1006766B8 (pt) 2021-05-25
PT2406225E (pt) 2013-09-19

Similar Documents

Publication Publication Date Title
PE20120171A1 (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh
PE20141064A1 (es) Compuestos de ester boronato y composciones farmaceuticas de los mismos
PE20141067A1 (es) Compuestos para el tratamiento de la adiccion
PE20141038A1 (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
PE20141124A1 (es) Derivados de imidazol fusionados, utiles como inhibidores de ido
BR112014015363A2 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
BR112014010576A8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
NZ607794A (en) N-acylsulfonamide apoptosis promoters
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
BR112014010420A2 (pt) inibidores de pak para o tratamento de distúrbios proliferativos celulares
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2011007192A (es) Composicion farmaceutica.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
BR112013028598A2 (pt) método para promover o crescimento de plantas
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112014007078A2 (pt) composição de controle de doença de plantas e seu uso
EA201590051A1 (ru) Новое соединение, обладающее способностью ингибировать фермент 11бета-hsd1, или его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, содержащая такое соединение в качестве активного ингредиента
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
MX2015008978A (es) Formas de sal de meglumina del acido 2-( (1r, 4r)-4-(4-(5- (benzoxazol-2-ilamino) piridin-2-il) fenil) ciclohexil)-acetico, y su uso como inhibidores de acil-coa-diacilglicerol-acil-transfer asa 1 (dgat1).
PE20091566A1 (es) (R)-N*6*-ETIL-6,7-DIHIDRO-5H-INDENO[5,6-d]TIAZOL-2,6-DIAMINA Y SUS SALES Y UN PROCEDIMIENTO PARA SU PREPARACION
BR112015004127A2 (pt) sais de composto benzotiazolona como agonista de beta-2-adrenorreceptor
UA110122C2 (uk) Біциклічні похідні як анальгетики, фармацевтична композиція на їх основі та спосіб усунення болю

Legal Events

Date Code Title Description
FG Grant, registration